Medindia

X

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

Tuesday, June 3, 2008 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., June 2 RigelPharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host aconference call with simultaneous webcast to discuss the preliminary resultsof its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, inpatients with B-cell non-Hodgkin's lymphomas on Tuesday, June 3, 2008 at 8:00a.m. EDT. Participating on the call will be Rigel senior management and theprincipal investigator on the study, Jonathan Friedberg, M.D., M.S.Sc.,Associate Professor of Medicine, James P. Wilmot Cancer Center, University ofRochester Medical Center.

Conference Call and Webcast Information

To access the live call, please dial 866-356-3095 (domestic) or617-597-5391 (international) 10 minutes prior to the start time and use thepasscode 61157501. A replay of the call will be available, in webcast andpodcast formats, at approximately 10:00 a.m. EDT on June 3, 2008 until June10, 2008. To access the replay, please dial 888-286-8010 (domestic) or617-801-6888 (international) and use the passcode 11043962. The conferencecall will also be webcast live and can be accessed from Rigel's website athttp://www.rigel.com. Please connect to Rigel's website several minutes priorto the start of the live webcast to ensure adequate time for any softwaredownloads that may be necessary.

Further information on R788 in B-cell lymphoma is available at Rigel'swebsite: http://www.rigel.com/rigel/lymphoma.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our goal is to file one new investigational new drug (IND)application in a significant indication each year. Rigel has achieved thisgoal every year since 2002. Our pioneering research focuses on intracellularsignaling pathways and related targets that are critical to diseasemechanisms. Rigel's productivity has resulted in strategic collaborations withlarge pharmaceutical partners to develop and market our product candidates.Rigel has product development programs in inflammatory/autoimmune diseasessuch as rheumatoid arthritis, thrombocytopenia and asthma, as well as incancer.Contact: Raul Rodriguez Phone: 650.624.1302 Email: invrel@rigel.com Media Contact: Susan C. Rogers, Alchemy Consulting, Inc. Phone: 650.430.3777 Email: susan@alchemyemail.com

SOURCE Rigel Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Outsourcing Trends, Metrics & Insights
S
Amylin Pharmaceuticals to Present Promising Data F...